{"product_id":"valneva-pestle-analysis","title":"Valneva PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political pressures, market dynamics, and biotech innovation are shaping Valneva’s trajectory in our concise PESTLE snapshot—perfect for investors and strategists seeking quick clarity; buy the full analysis to unlock deep regulatory, economic, and technological insights you can act on immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment vaccine procurement policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational health systems and government agencies remain Valneva’s primary customers for specialized vaccines like IXAVIA (travel) and VLA15 (Lyme), with public tenders accounting for over 70% of 2024 vaccine revenues; shifts in healthcare budgets or changes to national immunization programs can therefore materially affect order volume and revenue stability.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, heightened geopolitical tensions have driven several countries to boost domestic vaccine stockpiles and onshore manufacturing, increasing demand for secure supply chains and influencing Valneva’s contract negotiations and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational health organization partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva depends on partnerships with WHO and CEPI—CEPI pledged over $200m in 2021–2025 for emerging-pathogen vaccines—shaping distribution channels for Chikungunya and other candidates in low‑income markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal trade regulations and export controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s manufacturing footprint in Scotland, Sweden and Austria makes it highly sensitive to trade agreements and export controls; EU-UK post-Brexit adjustments raised customs checks that increased average cross-border lead times by up to 20% for some pharma suppliers in 2021–2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health funding and subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic-private partnerships and grants are crucial for Valneva’s vaccines targeting unmet needs; for example, EU and US grants contributed over 200 million euros to vaccine R\u0026amp;D across the sector in 2024, supporting pipeline stages without equity dilution.\u003c\/p\u003e\n\u003cp\u003ePolitical prioritization of neglected tropical diseases and biothreats channels non-dilutive capital—Valneva benefited from a 2023 CEPI\/UK grant program totaling ~100 million USD for emerging pathogen work.\u003c\/p\u003e\n\u003cp\u003eAusterity or reprioritization risks late-stage funding: cuts in 2024 health budgets in several EU states reduced available trial subsidies by an estimated 10–15%, pressuring private financing needs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrants\/partnerships provide non-dilutive R\u0026amp;D capital; sector received 200M+ EUR (2024).\u003c\/li\u003e\n\u003cli\u003eTargeted programs (CEPI\/UK) funneled ~100M USD to emerging pathogen vaccine efforts (2023).\u003c\/li\u003e\n\u003cli\u003ePublic austerity can cut trial subsidies ~10–15% (2024 EU examples), increasing private funding reliance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory agency independence and speed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe independence and speed of regulators like the FDA and EMA directly affect Valneva’s US and EU market timelines; FDA median review times for biologics were about 10 months in 2023 while EMA centralized procedure averages ~210 days, though COVID-era emergency paths cut this substantially.\u003c\/p\u003e\n\u003cp\u003ePolitical pressure can accelerate emergency use authorizations or prompt deeper safety reviews, changing revenue timing for Valneva’s pipeline products and contracted supply deals.\u003c\/p\u003e\n\u003cp\u003eValneva must invest in government affairs—its 2024 revenue of €156.6m and existing supply contracts hinge on timely approvals and regulatory predictability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA median biologics review ~10 months (2023)\u003c\/li\u003e\n\u003cli\u003eEMA centralized ~210 days average\u003c\/li\u003e\n\u003cli\u003e2024 revenue €156.6m—sensitive to approval timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: Grant‑reliant, \u0026gt;70% public tenders—regulatory delays and EU austerity risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva’s revenues (2024: €156.6m) are highly exposed to government procurement—public tenders \u0026gt;70% of vaccine sales—and to grant funding (EU\/US €200m+ sector grants in 2024; CEPI\/UK ~$100m program 2023). Regulatory timelines (FDA ~10 months; EMA ~210 days) and onshoring trends post‑2023 raise supply‑chain and pricing risks; 2024 EU austerity cut trial subsidies ~10–15%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e€156.6m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic tender share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSector grants (2024)\u003c\/td\u003e\n\u003ctd\u003e€200m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEPI\/UK (2023)\u003c\/td\u003e\n\u003ctd\u003e~$100m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA median review\u003c\/td\u003e\n\u003ctd\u003e~10 months (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMA centralized\u003c\/td\u003e\n\u003ctd\u003e~210 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Valneva across Political, Economic, Social, Technological, Environmental and Legal dimensions, with data-driven insights and forward-looking implications tailored to the vaccines\/biotech sector and Valneva’s markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise, PESTLE-segmented summary of Valneva that streamlines external risk, regulatory and market positioning discussions for meetings or slide decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva reports in euros while sizable revenues and R\u0026amp;D costs are in USD and GBP; in 2024 roughly 40% of revenues and ~55% of R\u0026amp;D spend were USD\/GBP-denominated, exposing net income to EUR\/USD and EUR\/GBP swings.\u003c\/p\u003e\n\u003cp\u003eBetween 2022–2024 EUR\/USD moved ~10% and EUR\/GBP ~7%, creating material FX gains\/losses for peers; similar volatility could swing Valneva’s EBIT by several million euros.\u003c\/p\u003e\n\u003cp\u003eAs of 2025 Valneva’s use of forward contracts and options is critical to stabilize margins amid unpredictable macro shifts and rate differentials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and capital costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ECB and Fed rate hikes pushed 2024 policy rates to ~4.25-5.5%, lifting average corporate borrowing costs and increasing Valneva’s interest expense risk; higher rates raised yields on safer assets, dampening investor appetite for biotech, where Valneva’s market cap was ~€1.2bn in late 2025, making equity raises potentially dilutive and costlier. Valneva’s planned manufacturing expansion (CAPEX hundreds of millions) depends on easier financing or stronger cash flows to avoid expensive debt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal travel industry recovery and growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant portion of valneva revenue derives from travel vaccines such as japanese encephalitis and cholera in these commercial contributed roughly product sales underscoring exposure to demand.\u003e\n\u003cpthe economic health of global tourism and business travel directly affects prophylactic vaccine uptake unwto reported international tourist arrivals reached levels in surpassed totals boosting travel-related healthcare spending.\u003e\n\u003cpas travel volumes peaked in with arrivals up about year-on-year valneva reported a noticeable uptick commercial product sales aiding its recovery after pandemic-related declines and strengthening revenue visibility.\u003e\n\u003c\/pas\u003e\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D investment climate and inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising inflation raised costs for specialized lab equipment by ~8-12% in 2024 and raw material prices for biologics surged ~6% YoY, squeezing Valneva’s R\u0026amp;D budgets for Lyme and Zika programs.\u003c\/p\u003e\n\u003cp\u003eFrance and EU inflation easing to ~3% in 2025 improves economic stability, helping Valneva better project multi-year investment needs for late-stage trials.\u003c\/p\u003e\n\u003cp\u003eManaging inflationary wage pressure—clinical scientists’ salaries up ~7%—while preserving vaccine innovation competitiveness remains a key economic challenge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLab equipment +8–12% (2024)\u003c\/li\u003e\n\u003cli\u003eBiologics raw materials +6% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eEU inflation ~3% (2025)\u003c\/li\u003e\n\u003cli\u003eSkilled-labor wages +7% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare reimbursement and pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic constraints on national healthcare budgets — OECD public health spending growth slowed to 1.5% in 2023 — increase pricing pressure on pharma, forcing Valneva to justify specialty vaccine costs to cost-conscious payers.\u003c\/p\u003e\n\u003cp\u003eValneva must balance high R\u0026amp;D and manufacturing costs (2024 revenue €146m vs. R\u0026amp;D spend ~€120m in 2023) with market-accessible pricing to secure reimbursement and long-term sustainability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD health spending growth 1.5% (2023)\u003c\/li\u003e\n\u003cli\u003eValneva 2024 revenue €146m\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D ~€120m (2023)\u003c\/li\u003e\n\u003cli\u003eNeed to demonstrate value for reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency, rates and cost pressures cloud vaccine-led growth but travel demand rebounds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFX exposure: ~40% revenues and ~55% R\u0026amp;D USD\/GBP (2024) creates EUR\/USD and EUR\/GBP earnings volatility; 2022–2024 moves ~10%\/7% impacted peers. Interest\/financing: ECB\/Fed rates ~4.25–5.5% (2024) raised borrowing costs; market cap ~€1.2bn (late 2025) makes equity raises costly. Demand\/costs: travel vaccines ~35% sales (2024); tourism ~95% of 2019 arrivals (2024); lab equipment +8–12%, biologics materials +6% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues USD\/GBP\u003c\/td\u003e\n\u003ctd\u003e~40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D USD\/GBP\u003c\/td\u003e\n\u003ctd\u003e~55% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTravel vaccine share\u003c\/td\u003e\n\u003ctd\u003e~35% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU\/US rates\u003c\/td\u003e\n\u003ctd\u003e~4.25–5.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab equipment inflation\u003c\/td\u003e\n\u003ctd\u003e+8–12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eValneva PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Valneva PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751849505145,"sku":"valneva-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/valneva-pestle-analysis.png?v=1772235357","url":"https:\/\/growthsharematrix.com\/products\/valneva-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}